Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The medical supply company is leaning on its plants in Canada, China, Ireland, and the U.K. to shore up reserves hurt by flooding of its North Carolina plant.

Analyst David Larsen from BTIG maintained a Buy rating on LifeMD (LFMD – Research Report) and keeping the price target at $12.00. David ...

Celebrities like Oprah Winfrey are touting it. People are microdosing it. And, in the midst of a national shortage of key ...

In a court filing, the FDA said it will reconsider its decision to bar compounded versions of tirzepatide (Mounjaro, Zepbound ...